AZD 1419

Drug Profile

AZD 1419

Alternative Names: AZ-1419; AZD-1419; Second-generation TLR-9 agonist - AstraZeneca/Dynavax

Latest Information Update: 03 Nov 2016

Price : $50

At a glance

  • Originator AstraZeneca; Dynavax Technologies
  • Class Antiasthmatics; DNA; Small molecules
  • Mechanism of Action Toll-like receptor 9 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Asthma
  • No development reported Chronic obstructive pulmonary disease

Most Recent Events

  • 01 Oct 2016 Phase-II clinical trials in Asthma in Denmark (Inhalation) (NCT02898662)
  • 19 Jan 2016 Dynavax and AstraZeneca amend research agreement; AstraZeneca will now conduct planned phase IIa trial
  • 13 Oct 2015 Phase-II trials in Asthma are being planned by AstraZeneca and Dynavax
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top